21

Nov2019
Pricing changes for Canada’s patented medicines are on their way and stakeholders are anticipating the release of the updated guidelines. How will the guidelines be operationalized? How will the new pharmacoeconomic factors be implemented? In an effort to answer these questions, PDCI has attempted to reverse-engineer the proposed Pharmacoeconomic Value ... Read More

31

Oct2019
3Sixty Public Affairs and PDCI Market Access have collaborated to create an infographic that unmasks the reality behind the assumptions Health Canada has used to justify its ongoing drug pricing reforms (through the Patented Medicine Prices Review Board). When it comes to federal drug pricing reform in Canada, there is ... Read More

25

Oct2019
PDCI is very pleased to welcome Keeley Farrell to the PDCI Team as Analyst, HTA and Clinical Evaluation. Keeley will help to support the development and preparation of the evidence-based clinical components of reimbursement and pricing submissions. She will also conduct research to support market access and ... Read More

22

Oct2019
PDCI presented a case study on the proposed amendments to the PMPRB regulations in Canada at the 2019 CAPT Conference held by the Canadian Association for Population Therapeutics. The objective of this policy analysis was to estimate the impact of the proposed PMPRB amendments on orphan drug prices. Review our poster ... Read More

12

Sep2019
REGISTRATION IS OPEN! Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members of the PDCI team ... Read More

28

Aug2019

04

Jul2019
PDCI Market Access Inc. is pleased to announce a new Strategic Partnership with Goeree Consulting Ltd (owned and operated by Ron Goeree). Goeree Consulting and PDCI are bringing together an exceptional level of experience and expertise in health economics, while further expanding ... Read More

14

Jun2019
Mark down June 26th, 2019 in your calendars. It is now widely expected the patented medicines price regulations will be in Canada Gazette Part II (CGII), volume 151 No.13, which will be released on June 26th. Draft PMPRB Guidelines for consultation will likely be published immediately following CGII publication. Comments earlier this week from Federal Health Minister Petitpas-Taylor, appeared to confirm these expectations. When asked in an interview surrounding when changes to the ... Read More

04

Jun2019
Article by PDCI Market Access featured in TELUS Health Insights Magazine Members of the PDCI Team recently published an article and case study highlighting the risks to Canadian drug launches posed by Health Canada’s proposed Patented Medicines Prices Review Board (PMPRB) price regulatory reforms. This article, which appears in the Spring ... Read More

02

May2019
PDCI is very pleased to welcome Julia Shen to the PDCI Team as Associate, Corporate Marketing and Policy Research, effective April 23, 2019! Ms. Shen’s addition to the team reflects PDCI’s focus on continued growth with our current and new clients and our objective to expand services responding to the ... Read More